China-based drug developer Adagene raises $69m led by General Atlantic

China-based drug developer Adagene raises $69m led by General Atlantic

Adagene is a clinical stage oncology-based biotech company

09 January, 2020

Adagene Inc F-Prime Capital General Atlantic GP Healthcare Capital Sequoia Capital China

Printed by Unregistered user on Tue, 29 Jul 2025 07:17:02 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

Sequoia Capital leads $50m Series C in Chinese biotech startup Adagene

General Atlantic promotes China healthcare practice head to MD

Read more from Greater China

HK’s Flow Capital Partners launches $125m credit fund, expands Asia focus

China’s FountainVest to buy major stake in Italy’s EuroGroup Laminations